NovoCure (NASDAQ:NVCR) Releases Quarterly Earnings Results, Beats Expectations By $0.19 EPS

NovoCure (NASDAQ:NVCR) posted its quarterly earnings results on Thursday. The medical equipment provider reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.19, FiscalAI reports. NovoCure had a negative net margin of 27.66% and a negative return on equity of 50.29%. The business had revenue of $174.35 million during the quarter, compared to analyst estimates of $174.40 million. During the same quarter in the previous year, the business posted ($0.61) EPS. The company’s quarterly revenue was up 8.2% compared to the same quarter last year.

Here are the key takeaways from NovoCure’s conference call:

• Novocure received FDA approval for Optune Pax for locally advanced pancreatic cancer, has begun U.S. launch activities, and filed regulatory applications in Europe and Japan.
• The company reported record 2025 net revenue of $655 million (Q4 revenue $174M) and issued 2026 guidance of $675M–$705M, while targeting adjusted EBITDA of –$20M to break even, reflecting a push toward profitability.
• Several near-term clinical catalysts are scheduled for 2026, including top-line readouts from PANOVA‑4 next month and the Phase 3 TRIDENT trial in Q2, plus expected completion of KEYNOTE‑D58 enrollment by year-end.
• Despite revenue growth, Novocure reported a full‑year net loss of $136 million and negative adjusted EBITDA (‑$34M for 2025), sees pressured gross margins (mid‑70s expected in 2026), and has drawn on credit while carrying $448 million in cash after repaying convertible notes.
• Leadership and operational changes include the resignation of the Chief Medical Officer and consolidation of scientific and clinical teams under Chief Innovation Officer Uri Weinberg, and a briefly suspended Medicare billing privilege that was promptly reinstated.

NovoCure Stock Down 8.3%

NVCR stock traded down $1.24 on Thursday, hitting $13.75. 5,490,062 shares of the company’s stock were exchanged, compared to its average volume of 2,907,818. NovoCure has a 12-month low of $9.82 and a 12-month high of $21.55. The firm has a 50 day moving average price of $12.71 and a two-hundred day moving average price of $12.63. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.50 and a current ratio of 1.55. The stock has a market cap of $1.54 billion, a P/E ratio of -8.54 and a beta of 0.73.

Institutional Investors Weigh In On NovoCure

Several institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC increased its holdings in shares of NovoCure by 56.7% during the first quarter. AQR Capital Management LLC now owns 28,728 shares of the medical equipment provider’s stock valued at $512,000 after acquiring an additional 10,394 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in NovoCure by 3.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 74,992 shares of the medical equipment provider’s stock valued at $1,336,000 after purchasing an additional 2,502 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in NovoCure by 5.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 993,670 shares of the medical equipment provider’s stock valued at $17,707,000 after purchasing an additional 52,180 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of NovoCure in the first quarter worth $87,000. Finally, Prudential Financial Inc. acquired a new stake in shares of NovoCure during the second quarter worth $216,000. Institutional investors and hedge funds own 84.61% of the company’s stock.

Trending Headlines about NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Medicare billing for NovoCure was restored, removing a key reimbursement overhang that had pressured near‑term revenue recognition and cash collection; this supports visibility into U.S. revenue and was cited by the market as a major positive catalyst. Novocure stock jumps after Medicare billing restored
• Positive Sentiment: Q4 results beat on EPS (loss of $0.22 vs. consensus -$0.41) and revenue was essentially in line at ~$174.4M (+8% YoY). The smaller-than-expected loss and steady top‑line growth reduce near‑term downside risk versus prior quarters. NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Management set FY‑2026 revenue guidance of $675M–$705M, modestly above street revenue consensus (~$670M), which signals expected continued growth and gives investors a clearer revenue trajectory for the year. Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
• Positive Sentiment: HC Wainwright raised its price target to $49 and reiterated a Buy rating, a high-profile analyst endorsement that could attract buyers given the large upside from current levels. Benzinga coverage of HC Wainwright PT raise
• Neutral Sentiment: Earnings‑call commentary highlighted record revenue and strategic growth plans (clinical and commercial expansion) but also discussed operational challenges and execution risks that management must resolve to sustain margin improvement — mixed signal for investors. NovoCure Q4 2025 Earnings Call Transcript Earnings call highlights
• Negative Sentiment: Despite the operational positives, NovoCure remains unprofitable (negative net margin and ROE) and analysts still model negative full‑year EPS; execution risk on margins and path to profitability keeps valuation under pressure. Zacks summary of Q4 results and financial metrics

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. HC Wainwright upped their target price on NovoCure from $47.00 to $49.00 and gave the stock a “buy” rating in a report on Thursday. Weiss Ratings reissued a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. Evercore set a $20.00 price objective on NovoCure in a research note on Monday, January 5th. Finally, Wedbush reiterated a “neutral” rating and issued a $18.00 target price on shares of NovoCure in a research note on Thursday, January 15th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, NovoCure currently has a consensus rating of “Hold” and a consensus price target of $26.93.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.